Title

A Study of AK-01 (LY3295668) in Solid Tumors
A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of AK-01 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
  • Phase

    Phase 1/Phase 2
  • Study Type

    Interventional
  • Study Participants

    13
This two-part study consists of a phase 1 dose escalation study in participants with locally advanced or metastatic solid tumors, and a phase 2 portion in up to 3 groups with either small cell lung cancer, breast cancer and/or one other solid tumor type.
Study Started
May 29
2017
Primary Completion
Apr 20
2020
Study Completion
Apr 20
2020
Results Posted
Jul 02
2021
Last Update
Jul 02
2021

Drug LY3295668

Oral capsules

  • Other names: AK-01, Erbumine

25 milligrams (mg) LY3295668 (Phase 1) Experimental

25 milligrams (mg) LY3295668 twice daily (BID) administered orally in 21-day cycles.

50 mg LY3295668 (Phase 1) Experimental

50 mg LY3295668 BID administered orally in 21-day cycles.

75 mg LY3295668 (Phase 1) Experimental

75 mg LY3295668 BID administered orally in 21-day cycles.

25 mg LY3295668 (Phase 2) Experimental

25 mg LY3295668 BID administered orally in 21-day cycles.

Criteria

Inclusion Criteria:

Have received at least 1 but no more than 4 prior systemic therapies
Have adequate organ function
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
Have estimated life expectancy greater than or equal to (≥)12 weeks
Have fully recovered from radiation therapy or surgery, and are recovering from any acute adverse effects of other cancer therapies
Have discontinued all chemotherapy, investigational therapy, molecularly-targeted therapy, and cancer-related hormonal therapy at least 14 days prior, biologic or immunotherapeutic therapy at least 21 days prior, or mitomycin-C or nitrosoureas at least 6 weeks prior
Female participants with reproductive potential agree to use 2 forms of highly effective contraception during the study and for the following 3 months
Male participants must use a barrier method of contraception during the study and for the following 3 months

Phase 1

Have evidence of a solid tumor that is locally advanced and/or metastatic (excluding primary brain tumor)

Phase 2

Have disease measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1

Have evidence of a solid tumor that is locally advanced and/or metastatic, and in:

Small Cell Lung Cancer (SCLC), must have failed platinum-containing therapy
Breast Cancer, be Estrogen Receptor positive and/or Progesterone Receptor positive, but Human Epidermal Growth Factor Receptor 2 (HER2) negative, and must have failed a hormone therapy and a Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor
Triple negative breast cancer (TNBC) and failed standard therapy
Squamous cell cancers of the head neck associated with the human papilloma virus (HPV), and have failed standard therapy
Other solid tumor type that has been approved by the sponsor

Exclusion Criteria:

Have symptomatic central nervous system (CNS) metastasis (unless asymptomatic and not current receiving corticosteroids) or a primary tumor of the CNS
Have a medical condition that precludes participation (swallowing disorder, organ transplant, pregnant or nursing, HIV, active Hepatitis B or C, cardiac disease, history of major surgery in upper gastrointestinal (GI) tract or GI disease, hypokalemia, hypomagnesaemia or hypocalcaemia that cannot be controlled)

Summary

25 Milligrams (mg) LY3295668

50 mg LY3295688

75 mg LY3295688

All Events

Event Type Organ System Event Term 25 Milligrams (mg) LY3295668 50 mg LY3295688 75 mg LY3295688

Phase 1: Maximum Tolerated Dose

Maximum Tolerated Dose (MTD) was defined as the dose immediately below the dose at which ≥2/3, ≥2/6, or ≥3/9 participants in a cohort experienced a dose limiting toxicity (DLT) during the first 21 days of treatment (Cycle 1) in Phase 1.

LY3295668 Phase 1

25.0
milligram (mg)

Phase 2: Percentage of Participants Who Achieved Partial Response (PR) or Complete Response (CR) [Objective Response Rate (ORR)]

Objective response rate (ORR) was defined as a percentage of responders who achieved complete response or partial response (CR+PR) as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1). Complete response (CR) is defined as disappearance of all target (and non-target) lesions, and no appearance of new lesion. Partial response (PR) was defined as at least a 30% decrease in the sum of longest diameters (LD) of target lesions, taking as reference the baseline sum of LD, no progression of non-target lesions, and no appearance of new lesions.

25 mg LY3295668 (Phase 2)

Phase 1: Number of Participants With One or More Treatment-Emergent Adverse Events

A treatment-emergent adverse event (AE) is an AE that started or worsened (increased in severity) from the treatment start date to 30 days after the treatment end date. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.

25 mg LY3295668 (Phase 1)

50 mg LY3295668 (Phase 1)

75 mg LY3295668 (Phase 1)

Phase 2: Number of Participants With One or More Treatment-Emergent Adverse Events

A treatment-emergent adverse event (AE) is an AE that started or worsened (increased in severity) from the treatment start date to 30 days after the treatment end date. A summary of other non-serious Adverse Events (AEs), and all Serious Adverse Events (SAE's), regardless of causality, is located in the Reported Adverse Events section.

25 mg LY3295668 (Phase 2)

Phase 2: Pharmacokinetic (PK): Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post-dose (AUC[0-12]) (Phase 2)

Area under the plasma concentration-time curve for LY3295668 from time zero to 12 hours.

25 mg LY3295668 (Phase 2)

Phase 2: PK: Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours Post-dose (AUC[0-24])

Area under the plasma concentration-time curve for LY3295668 from time zero to 24 hours.

25 mg LY3295668 (Phase 2)

Phase 2: PK: Maximum Observed Plasma Concentration (Cmax)

Maximum observed plasma concentration for LY3295668.

25 mg LY3295668 (Phase 2)

Day 1

Day 15

Phase 2: PK: Time of Maximum Observed Plasma Concentration (Tmax)

Time of maximum observed plasma concentration of LY3295668.

25 mg LY3295668 (Phase 2)

Day 1

Day 15

Phase 2: PK: Apparent Terminal Elimination Half-life (t1/2)

Apparent terminal elimination half-life of LY3295668.

25 mg LY3295668 (Phase 2)

Phase 1: Number of Participants With Worst Post-Baseline Grade >=3 White Blood Cell Count (WBC)

Presented are participants with the worst post-baseline WBC Grade >= 3 using the National Cancer Institute (NCI) Common Terminology Criteria For Adverse Events version 4.03 (CTCAE v4.03). where Grade 1: < Lower Limit Normal (LLN) - 3000/mm3; <LLN - 3.0 x10e9/L, Grade 2: <3000 - 2000/mm3; <3.0 - 2.0 x10e9/L, Grade 3: <2000 - 1000/mm3; <2.0 1.0 x10e9/L, Grade 4: <1000/mm3; <1.0 x10e9/L.

25 mg LY3295668 (Phase 1)

50 mg LY3295668 (Phase 1)

75 mg LY3295668 (Phase 1)

Phase 1: Number of Participants With Worst Post-Baseline Grade >=3 Neutrophils (Segmented and Blended)

Presented are participants with the worst post-baseline neutrophils Grade >=3 using the NCI-CTCAE v4.03 where Grade 1: < LLN - 1500/mm3; <LLN - 1.5 x10e9/L, Grade 2: <1500 - 1000/mm3; <1.5 - 1.0 x10e9/L, Grade 3: <1000 - 500/mm3; <1.0 - 0.5 x10e9/L, Grade 4: <500/mm3; <0.5 x 10e9/L.

25 mg LY3295668 (Phase 1)

50 mg LY3295668 (Phase 1)

75 mg LY3295668 (Phase 1)

Phase 2: PK: Apparent Total Plasma Clearance (CL/F)

Apparent total plasma clearance of LY3295668.

25 mg LY3295668 (Phase 2)

Phase 1: Number of Participants With Worst Post-Baseline Grade >=3 Lymphocytes

Presented are participants with the worst post-baseline lymphocytes Grade >=3 using the NCI-CTCAE version 4.03 where Grade 1: <LLN - <800/mm3, <LLN - 0.8 x 10e9/L, Grade 2: <800 - 500/mm3; <0.8 - 0.5 x 10e9/L, Grade 3: <500 - 200/mm3; <0.5 - 0.2 x 10e9/L, <200mm3; <0.2 x 10e9/L.

25 mg LY3295668 (Phase 1)

50 mg LY3295668 (Phase 1)

75 mg LY3295668 (Phase 1)

Phase 2: PK: Apparent Volume of Distribution (Vz/F)

Apparent volume of distribution of LY3295668.

25 mg LY3295668 (Phase 2)

Total

13
Participants

Age, Categorical

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

Sex: Female, Male

Overall Study

25 Milligrams (mg) LY3295668 (Phase 1)

50 mg LY3295668 (Phase 1)

75 mg LY3295668 (Phase 1)

25 mg LY3295668 (Phase 2)